Patent application number | Description | Published |
20080253988 | Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases - A compound of formula (I): wherein the substituents are as defined in the specification as inhibitor of C-Jun N terminal Kinases (JNK) and P-38 Kinases. | 10-16-2008 |
20080255160 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 10-16-2008 |
20080312307 | MAPK/ERK KINASE INHIBITORS - Compounds are provided for inhibition of MEK that comprise: | 12-18-2008 |
20090118324 | MAPK/ERK KINASE INHIBITORS - Compounds are provided for use with MEK that comprise: | 05-07-2009 |
20090124595 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 05-14-2009 |
20090156557 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 06-18-2009 |
20090246198 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF - Compounds of the following formula are provided: | 10-01-2009 |
20090247554 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise (I), (II), (III), (IV): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 10-01-2009 |
20090264409 | Bicyclic Heterocyclic p-38 Kinase Inhibitors - Provided are bicyclic heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders. | 10-22-2009 |
20090312288 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 12-17-2009 |
20100004298 | P-38 INHIBITORS - Provided are 5-membered heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders. | 01-07-2010 |
20100113413 | MAPK/ERK Kinase Inhibitors - Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: | 05-06-2010 |
20100120717 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture in comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 05-13-2010 |
20100130518 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 05-27-2010 |
20100160633 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 06-24-2010 |
20100190816 | KINASE INHIBITORS - Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: | 07-29-2010 |
20100204471 | MAPK/ERK KINASE INHIBITORS - Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. | 08-12-2010 |
20100216765 | KINASE INHIBITORS - Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of: | 08-26-2010 |
20110021515 | DIHYROFUROPYRMINDINE COMPOUNDS - The present invention provides mTOR inhibitors of the formula | 01-27-2011 |
20110053921 | HEXAHYDROOXAZINOPTERINE COMPOUNDS - The present invention provides mTOR inhibitors of the formula | 03-03-2011 |
20110065733 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 03-17-2011 |
20110136780 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK - Disclosed are JAK inhibitors of formula I | 06-09-2011 |
20110152273 | FUSED HETEROAROMATIC PYRROLIDINONES - Disclosed are compounds of Formula 1, | 06-23-2011 |
20110178070 | PI3K/mTOR INHIBITORS - The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula: | 07-21-2011 |
20110190261 | MAPK/ERK Kinase Inhibitors - Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: | 08-04-2011 |
20120095233 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 04-19-2012 |
20120178924 | HEXAHYDROOXAZINOPTERINE COMPOUNDS - The present invention relates to intermediates of the formula | 07-12-2012 |
20120220575 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES - Disclosed are compounds of Formula 1, | 08-30-2012 |
20120252761 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 10-04-2012 |
20130116260 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS - Disclosed are compounds of Formula 1, | 05-09-2013 |
20130245031 | FUSED HETEROAROMATIC PYRROLIDINONES - Disclosed are compounds of Formula 1, | 09-19-2013 |
20140309219 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES - Disclosed are compounds of Formula 1, | 10-16-2014 |